Compare Gilead Sciences, Inc. (GILD) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ArcelorMittal SA — how do they compare? Gilead Sciences, Inc. trades at $134.5 (market cap $163.51B), while ArcelorMittal SA trades at $65.87 (market cap $50.29B). The key difference: Gilead Sciences, Inc. is far larger — about 3.3× ArcelorMittal SA's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MT | |
|---|---|---|
Market Cap | $163.51B | $50.29B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $71.65 |
52-Week Low | $108.22 | $30.39 |
Enterprise Value | $178.05B | $59.61B |
Dividend Yield | 2.49% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ArcelorMittal (MT) trades at $65.92, down 1.6% on the day, yet maintains a bullish technical outlook with strong moving average signals. The company shows improving fundamentals with three consecutive quarterly earnings beats and a net income margin of 4.71% for 2025. Recent positive catalysts include a share buyback program expansion and strategic AI collaboration with AWS to enhance operational efficiency and lower-carbon steel production.
The stock presents a value opportunity with a P/E of 17.7 and P/B below 1, supported by a 50% analyst buy rating. Key risks include declining revenue trends from $79.8B in 2022 to $61.4B in 2025 and heavy capital expenditures impacting cash flow. Near-term performance hinges on Q2 2026 earnings versus the $1.17 EPS expectation and steel demand stability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
